The Latest Breaking News from Lupus

Possible treatment for rheumatoid arthritis and multiple sclerosis

Study finds CAR T-cell treatment sends lupus into remission, raising hopes it could be used to treat diseases such as multiple sclerosis

Pauline Follett, who lives with cerebral lupus, has had two National Disability Insurance Scheme applications rejected within three years. According to a Disability Advocacy NSW report, people in remote areas of NSW face challenges in providing the evidence required.

Here's a roundup of top developments in the biotech space over the last 24 hours:

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Three patients have undergone CAR T-cell therapy, which genetically alters their immune system to protect their organs

Aurinia Pharmaceuticals hired a trio of executives in a move that suggests it's nowhere near a buyout — and AUPH stock plummeted Friday.

Six days after the Supreme Court struck down the right to abortion, lupus patient Becky Schwarz got an unexpected message from her rheumatologist.

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

MYSURU